5:24 PM
 | 
Jan 08, 2013
 |  BC Extra  |  Company News

EC approves Krystexxa pegloticase

The European Commission approved Krystexxa pegloticase from Savient Pharmaceuticals Inc. (NASDAQ:SVNT) to treat severe chronic tophaceous gout in adult patients. The drug...

Read the full 99 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >